Articles
26 result(s) for 'Lecanemab' within Alzheimer's Research & Therapy
Page 1 of 1
-
Citation: Alzheimer's Research & Therapy 2022 14:70
-
Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer’s disease
Lecanemab (BAN2401) is a humanized IgG1 monoclonal ... this trial, subjects were randomized to five lecanemab dose regimens or placebo. The primary efficacy ... of sensitivity analyses evaluating the consistency ...
Citation: Alzheimer's Research & Therapy 2022 14:182 -
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
Lecanemab (BAN2401), an IgG1 monoclonal antibody, ... to assess 3 doses across 2 regimens of lecanemab versus placebo in early Alzheimer’s disease,...
Citation: Alzheimer's Research & Therapy 2021 13:80 -
Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study
Lecanemab, a humanized IgG1 monoclonal antibody that targets ... core and OLE) supporting the effectiveness of lecanemab.
Citation: Alzheimer's Research & Therapy 2022 14:191 -
Aβ42 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer’s disease brain extracts
In Alzheimer’s disease (AD), amyloid-β 1–42 (Aβ42) neurotoxicity stems mostly from its soluble oligomeric aggregates. Studies of such aggregates have been hampered by the lack of oligomer-specific research too...
Citation: Alzheimer's Research & Therapy 2022 14:196 -
Long-term effects of immunotherapy with a brain penetrating Aβ antibody in a mouse model of Alzheimer’s disease
Brain-directed immunotherapy is a promising strategy to target amyloid-β (Aβ) deposits in Alzheimer’s disease (AD). In the present study, we compared the therapeutic efficacy of the Aβ protofibril targeting an...
Citation: Alzheimer's Research & Therapy 2023 15:90 -
Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
Citation: Alzheimer's Research & Therapy 2021 13:98 -
Five-mer peptides prevent short-term spatial memory deficits in Aβ25-35-induced Alzheimer’s model mouse by suppressing Aβ25-35 aggregation and resolving its aggregate form
The development of drugs for Alzheimer’s disease (AD), which is related to the misfolding and aggregation of amyloid-β (Aβ), is high in demand due to the growing number of AD patients. In this study, we screen...
Citation: Alzheimer's Research & Therapy 2023 15:83 -
Expected and diagnosed rates of mild cognitive impairment and dementia in the U.S. Medicare population: observational analysis
With the emergence of disease-modifying Alzheimer’s treatments, timely detection of early-stage disease is more important than ever, as the treatment will not be indicated for later stages. Contemporary popula...
Citation: Alzheimer's Research & Therapy 2023 15:128 -
Therapeutic preference for Alzheimer’s disease treatments: a discrete choice experiment with caregivers and neurologists
Alzheimer’s disease (AD) is a major global health crisis in need of more effective therapies. However, difficult choices to optimize value-based care will need to be made. While identifying preferred therapeut...
Citation: Alzheimer's Research & Therapy 2023 15:60 -
Recruitment of pre-dementia participants: main enrollment barriers in a longitudinal amyloid-PET study
The mismatch between the limited availability versus the high demand of participants who are in the pre-dementia phase of Alzheimer’s disease (AD) is a bottleneck for clinical studies in AD. Nevertheless, pote...
Citation: Alzheimer's Research & Therapy 2023 15:189 -
Long-term normalization of calcineurin activity in model mice rescues Pin1 and attenuates Alzheimer’s phenotypes without blocking peripheral T cell IL-2 response
Current treatments for Alzheimer’s disease (AD) have largely failed to yield significant therapeutic benefits. Novel approaches are desperately needed to help address this immense public health issue. Data sug...
Citation: Alzheimer's Research & Therapy 2023 15:179 -
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
This review describes the research and development process of gantenerumab, a fully human anti-amyloid monoclonal antibody in development to treat early symptomatic and asymptomatic Alzheimer’s disease (AD). A...
Citation: Alzheimer's Research & Therapy 2022 14:178 -
Readthrough isoform of aquaporin-4 (AQP4) as a therapeutic target for Alzheimer’s disease and other proteinopathies
The glymphatic system is a crucial component in preserving brain homeostasis by facilitating waste clearance from the central nervous system (CNS). Aquaporin-4 (AQP4) water channels facilitate the continuous i...
Citation: Alzheimer's Research & Therapy 2023 15:170 -
Perspectives and challenges in patient stratification in Alzheimer’s disease
Patient stratification is the division of a patient population into distinct subgroups based on the presence or absence of particular disease characteristics. As patient stratification can be used to account f...
Citation: Alzheimer's Research & Therapy 2022 14:112 -
Longitudinal resting-state EEG in amyloid-positive patients along the Alzheimer’s disease continuum: considerations for clinical trials
To enable successful inclusion of electroencephalography (EEG) outcome measures in Alzheimer’s disease (AD) clinical trials, we retrospectively mapped the progression of resting-state EEG measures over time in...
Citation: Alzheimer's Research & Therapy 2023 15:182 -
Centralizing prescreening data collection to inform data-driven approaches to clinical trial recruitment
Recruiting to multi-site trials is challenging, particularly when striving to ensure the randomized sample is demographically representative of the larger disease-suffering population. While previous studies h...
Citation: Alzheimer's Research & Therapy 2023 15:88 -
Feasibility and therapeutical potential of local intracerebral encapsulated cell biodelivery of BDNF to AppNL−G−F knock-in Alzheimer mice
Alzheimer’s disease (AD) is an age-related disease characterized by altered cognition, neuroinflammation, and neurodegeneration against which there is presently no effective cure. Brain-derived neurotrophic fa...
Citation: Alzheimer's Research & Therapy 2023 15:137 -
How healthy participants value additional diagnostic testing with amyloid-PET in patients diagnosed with mild cognitive impairment — a bidding game experiment
To estimate the perceived value of additional testing with amyloid-PET in Euros in healthy participants acting as analogue patients with mild cognitive impairment (MCI).
Citation: Alzheimer's Research & Therapy 2023 15:208 -
Avoiding future controversies in the Alzheimer’s disease space through understanding the aducanumab data and FDA review
Key points of disagreement between the aducanumab FDA statistical review, which had primarily negative conclusions, and the clinical review, which had primarily positive conclusions, were investigated. Results...
Citation: Alzheimer's Research & Therapy 2023 15:98 -
Home-based transcranial alternating current stimulation (tACS) in Alzheimer’s disease: rationale and study design
Gamma (γ) brain oscillations are dysregulated in Alzheimer’s disease (AD) and can be modulated using transcranial alternating stimulation (tACS). In the present paper, we describe the rationale and design of a...
Citation: Alzheimer's Research & Therapy 2023 15:155 -
A metagenomic study of gut viral markers in amyloid-positive Alzheimer’s disease patients
Mounting evidence suggests the involvement of viruses in the development and treatment of Alzheimer’s disease (AD). However, there remains a significant research gap in metagenomic studies investigating the gu...
Citation: Alzheimer's Research & Therapy 2023 15:141 -
Whole-brain modeling of the differential influences of amyloid-beta and tau in Alzheimer’s disease
Citation: Alzheimer's Research & Therapy 2023 15:210 -
Identification of methylation-regulated genes modulating microglial phagocytosis in hyperhomocysteinemia-exacerbated Alzheimer’s disease
Hyperhomocysteinemia (HHcy) has been linked to development of Alzheimer’s disease (AD) neuropathologically characterized by the accumulation of amyloid β (Aβ). Microglia (MG) play a crucial role in uptake of A...
Citation: Alzheimer's Research & Therapy 2023 15:164 -
Blood–brain barrier penetrating neprilysin degrades monomeric amyloid-beta in a mouse model of Alzheimer’s disease
Aggregation of the amyloid-β (Aβ) peptide in the brain is one of the key pathological events in Alzheimer’s disease (AD). Reducing Aβ levels in the brain by enhancing its degradation is one possible strategy t...
Citation: Alzheimer's Research & Therapy 2022 14:180 -
The therapeutic landscape of tauopathies: challenges and prospects
Tauopathies are a group of neurodegenerative disorders characterized by the aggregation of the microtubule-associated protein tau. Aggregates of misfolded tau protein are believed to be implicated in neuronal ...
Citation: Alzheimer's Research & Therapy 2023 15:168
Follow
- ISSN: 1758-9193 (electronic)